Yong P Hwang1, Hye G Jeong. 1. Department of Toxicology, College of Pharmacy, Chungnam National University, Daejeon, Korea.
Abstract
BACKGROUND AND PURPOSE: Population studies have revealed that treatment with the anti-diabetic drug metformin is significantly associated with reduced cancer risk, but the underlying mode of action has not been elucidated. The aim of our study was to determine the effect of metformin on tumour invasion and migration, and the possible mechanisms, using human fibrosarcoma HT-1080 cells. EXPERIMENTAL APPROACH: We employed invasion, migration and gelatin zymography assays to characterize the effect of metformin on HT-1080 cells. Transient transfection assays were performed to gene promoter activities, and immunoblot analysis to study its molecular mechanisms of action. KEY RESULTS: Metformin inhibited migration and invasion by HT-1080 cells at sub-toxic concentrations. In these cells, metformin also suppressed phorbol-12-myristate-13-acetate (PMA)-enhanced levels of matrix metalloproteinases-9 (MMP-9) protein, mRNA and transcription activity through suppression of activator protein-1 (AP-1) activation. In addition, metformin strongly repressed the PMA-induced phosphorylation of extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and protein kinase C(PKC)alpha, whereas the phosphorylation of p38 mitogen-activated protein kinase was not affected by metformin. Metformin decreased the PMA-induced Ca(2+) influx. Furthermore, treatment with an intracellular Ca(2+) chelator (BAPTA-AM) or a selective calmodulin antagonist (W7) markedly decreased PMA-induced MMP-9 secretion and cell migration, as well as activation of ERK and JNK/AP-1. CONCLUSIONS AND IMPLICATIONS: Metformin inhibited PMA-induced invasion and migration of human fibrosarcoma cells via Ca(2+)-dependent PKCalpha/ERK and JNK/AP-1-signalling pathways. Metformin therefore has the potential to be a potent anti-cancer drug in therapeutic strategies for fibrosarcoma metastasis.
BACKGROUND AND PURPOSE: Population studies have revealed that treatment with the anti-diabetic drug metformin is significantly associated with reduced cancer risk, but the underlying mode of action has not been elucidated. The aim of our study was to determine the effect of metformin on tumour invasion and migration, and the possible mechanisms, using humanfibrosarcoma HT-1080 cells. EXPERIMENTAL APPROACH: We employed invasion, migration and gelatin zymography assays to characterize the effect of metformin on HT-1080 cells. Transient transfection assays were performed to gene promoter activities, and immunoblot analysis to study its molecular mechanisms of action. KEY RESULTS:Metformin inhibited migration and invasion by HT-1080 cells at sub-toxic concentrations. In these cells, metformin also suppressed phorbol-12-myristate-13-acetate (PMA)-enhanced levels of matrix metalloproteinases-9 (MMP-9) protein, mRNA and transcription activity through suppression of activator protein-1 (AP-1) activation. In addition, metformin strongly repressed the PMA-induced phosphorylation of extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and protein kinase C(PKC)alpha, whereas the phosphorylation of p38 mitogen-activated protein kinase was not affected by metformin. Metformin decreased the PMA-induced Ca(2+) influx. Furthermore, treatment with an intracellular Ca(2+) chelator (BAPTA-AM) or a selective calmodulin antagonist (W7) markedly decreased PMA-induced MMP-9 secretion and cell migration, as well as activation of ERK and JNK/AP-1. CONCLUSIONS AND IMPLICATIONS: Metformin inhibited PMA-induced invasion and migration of humanfibrosarcoma cells via Ca(2+)-dependent PKCalpha/ERK and JNK/AP-1-signalling pathways. Metformin therefore has the potential to be a potent anti-cancer drug in therapeutic strategies for fibrosarcoma metastasis.
Authors: Marie E Beckner; Glenn T Gobbel; Roger Abounader; Fatima Burovic; Naomi R Agostino; John Laterra; Ian F Pollack Journal: Lab Invest Date: 2005-12 Impact factor: 5.662
Authors: Vladimir N Anisimov; Lev M Berstein; Peter A Egormin; Tatiana S Piskunova; Irina G Popovich; Mark A Zabezhinski; Irina G Kovalenko; Tatiana E Poroshina; Anna V Semenchenko; Mauro Provinciali; Francesca Re; Claudio Franceschi Journal: Exp Gerontol Date: 2005 Aug-Sep Impact factor: 4.032
Authors: Mengwei Zang; Adriana Zuccollo; Xiuyun Hou; Daisuke Nagata; Kenneth Walsh; Haya Herscovitz; Peter Brecher; Neil B Ruderman; Richard A Cohen Journal: J Biol Chem Date: 2004-09-14 Impact factor: 5.157
Authors: Roger C Zhu; Kirk Rattanakorn; Steven Pham; Divya Mallam; Thomas McIntyre; Moro O Salifu; Irini Youssef; Samy I McFarlane; Shivakumar Vignesh Journal: Colorectal Cancer Date: 2017-06-21
Authors: Stephanie C Casey; Monica Vaccari; Fahd Al-Mulla; Rabeah Al-Temaimi; Amedeo Amedei; Mary Helen Barcellos-Hoff; Dustin G Brown; Marion Chapellier; Joseph Christopher; Colleen S Curran; Stefano Forte; Roslida A Hamid; Petr Heneberg; Daniel C Koch; P K Krishnakumar; Ezio Laconi; Veronique Maguer-Satta; Fabio Marongiu; Lorenzo Memeo; Chiara Mondello; Jayadev Raju; Jesse Roman; Rabindra Roy; Elizabeth P Ryan; Sandra Ryeom; Hosni K Salem; A Ivana Scovassi; Neetu Singh; Laura Soucek; Louis Vermeulen; Jonathan R Whitfield; Jordan Woodrick; Annamaria Colacci; William H Bisson; Dean W Felsher Journal: Carcinogenesis Date: 2015-06 Impact factor: 4.944
Authors: K Kalinsky; T Zheng; H Hibshoosh; X Du; P Mundi; J Yang; S Refice; S M Feldman; B Taback; E Connolly; K D Crew; M A Maurer; D L Hershman Journal: Clin Transl Oncol Date: 2016-06-15 Impact factor: 3.405
Authors: Thomas I Barron; Evelyn M Flahavan; Linda Sharp; Kathleen Bennett; Kala Visvanathan Journal: Cancer Res Date: 2014-08-01 Impact factor: 12.701
Authors: Elena A Goncharova; Dmitry A Goncharov; Melane L James; Elena N Atochina-Vasserman; Victoria Stepanova; Seung-Beom Hong; Hua Li; Linda Gonzales; Masaya Baba; W Marston Linehan; Andrew J Gow; Susan Margulies; Susan Guttentag; Laura S Schmidt; Vera P Krymskaya Journal: Cell Rep Date: 2014-04-13 Impact factor: 9.423